MED CHECK The Informed Prescriber
launched on Jan 2015 in Japan, integrating two ISDB member bulletins:
Med Check and The Informed Prescriber

Rigorously Independent and reliable Information for informed decision-making on treatment and healthcare, published by Non-Profit Organization Japan Institute of Pharmacovigilance (NOPJIP). Med Check TIP is financed by its subscribers. No advertising, No shareholders, No sponsors.

Here is the 8th issue of “Med Check TIP” in English
We will publish at least three issues a year

Aug. 2017,Vol.3, No.8ContentsPDF(7.8MB)
Apr. 2017,Vol.3, No.7ContentsPDF(3.3MB)
Dec. 2016,Vol.2, No.6ContentsPDF(9.9MB)
Aug. 2016,Vol.2, No.5ContentsPDF(6.2MB)
Supplementary material:PDF(6.3MB)
Apr. 2016,Vol.2, No.4ContentsPDF(16MB)
Supplement: Cochrane commentsPDF(1.3MB)
Dec. 2015,Vol.1, No.3ContentsPDF(7MB)
Aug. 2015,Vol.1, No.2ContentsPDF(5MB)
Apr. 2015,Vol.1, No.1ContentsPDF(3MB)

CONTENTS August 2017, Vol.3, No.8 PDF(7.8MB)

Is the intervention really necessary?         p13
The importance of the epidemiologic evidence
Screening does not reduce cervical cancer deaths    p14
The best and only protective measure is to have adequate nutrition and sleep
Pneumococcal and Hib vaccines for children      p20
Harms may outweigh benefits: not recommended

CONTENTS April 2017, Vol.3, No.7 PDF(3.3MB)

Time to wake up from a nightmare
"cholesterol=devil" hypothesis
New products
Anti PD-1 antibody: pembrolizumab
Effective only for non-small cell lung cancer of specific type
New Cholesterol Lowering Agents (PCSK9 Inhibitors)
Infection and neurological diseases increase.
Top 1 most read for 5 months: paper on cholesterol
RCTs of cholesterol lowering agents of different classes were cancelled in succession

CONTENTS December 2016, Vol.2, No.6 PDF(9.9MB)

Don’t be misled by new “mab” drugs p28
New products
Nivolumab (brand name: Opdivo) p29-34
Benefit and harm on survival offset each other: strict restriction on use is needed
GLP-1 Agonists (liraglutide) p35-42
No evidence of improving prognosis in patients with diabetes: Not recommended

CONTENTS Aug. 2016, Vol.2, No.5 PDF(6.2MB)

Epidemiologists and biostatisticians, be honest!
Adverse Reactions
Symptoms after HPV vaccine:
Typical "frailty exclusion bias" in Nagoya City study
Critical comments from theoretical viewpoints
Supplementary material:
Frailty exclusion bias:A theoretical basis and practical influences on Nagoya City Study:PDF(6.3MB)
Adverse Reactions
Pioglitazone (brand name: Actos) and bladder cancer: A new type "time-related bias"

CONTENTS Apr. 2016, Vol.2, No.4 PDF(16MB)

“Talk about harm, not risk”
New Products
Memantine (brand name: Memary): No value for dementia
An NMDA antagonist, memantine may induce neurotoxicity
Too many withdrawn cases due to adverse reactions
Dutasteride (Zagallo®) for Androgenetic alopecia:
Good in theory, too harmful in practice: cancer, sexual dysfunctions, suicide
Cochrane team criticises the ECDC experts' draft advice on oseltamivir use:
Supplementary material:
Critical comments to ECDC by Cochrane team PDF(1.3MB)

CONTENTS Dec. 2015,Vol.1, No.3 PDF(7MB)

“Surrogate endpoint” qualify “real advance”?
New Products
Anti-HCV agent LDV/SOF combination (brand name: Harvoni)
8 week treatment may be better to reduce harm and costs with same efficacy
Febuxostat(brand name: Febric): Inferior to allopurinol
Too frequent cardiovascular events, gouty attacks, serious allergy
Is Alteplase Beneficial for Treating Ischemic Stroke?
No proven efficacy if it is given 1.5 hours after onset

CONTENTS Aug. 2015,Vol.1, No.2 PDF(5MB)

We want good medicines!
New Products
Dabigatran: potentially harmful: See also Supplementary materials: PDF (4.6MB)
The safe use is compromised without monitoring and an antagonist
Optimal dose may be lower: Subgroup analysis indicates
Information for the patient (Dabigatran)
Too harmful and expensive for general use as a laxative
Plain language summary
Adverse Reactions
Propofol-induced death in children: at a Univ. Hospital
Plain language summary
Plain Language summary
Dabigatran (information for the patient)

CONTENTS Apr. 2015,Vol.1, No.1 PDF(3MB)

An independent drug bulletin for medical practice
New Products
# SGLT-2 inhibitors: Unacceptable products--can we call these “medicines”?
Were the harms warned after marketing known before approval?
# Methadone (Limited use): Useful only in opioid rotation with special precautions
Why is it useful in opioid rotation? What precautions are needed?
# H.pylori eradication may shorten life span:
Gastric cancer decreases by H.pylori eradication. Why life span may shorten?
What diseases and why other diseases increase? What are the underlying mechanisms?
# Harm of HPV vaccine: Latest information and examination of epidemiological studies
“I have never seen such serious diseases in teen age girls”, many specialists say.
Do RCTs prove the safety of HPV vaccines?
Do epidemiologic studies prove the safety of HPV vaccines?
Is the prevalence same as the incidence? What is the “healthy vaccinee effect”
Plain Language summary
# SGLT-2 inhibitors: inaccurate to call these “medicines”
What is diabetes? What is insulin?
Target of treatment is NOT to normalize the blood glucose level. Then what is the target?
# "Pylori" bacteria removal may shorten life
# Harm of HPV vaccine: epidemiologic studies do not prove safety